drug
as of 2026-07-01NSA-789
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Wyeth is now a wholly owned subsidiary of Pfizer
2 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
2
Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder
NCT00892021Phase 1Withdrawn
Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789
NCT00795730Phase 1Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
trial
indication
indication
indication
indication
indication